Preclinical and clinical aspects of P2X receptors as a common route in different diseases: A meeting report

Luke Tattersall; Elena Adinolfi; Luca Antonioli; Ankita Agrawal

doi:10.1007/s11302-024-09994-x

Preclinical and clinical aspects of P2X receptors as a common route in different diseases: A meeting report

Purinergic Signal. 2024 Feb 20. doi: 10.1007/s11302-024-09994-x. Online ahead of print.

Authors

Luke Tattersall¹, Elena Adinolfi², Luca Antonioli³, Ankita Agrawal⁴

Affiliations

¹ The Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, School of Medicine & Population Health, The University of Sheffield, Sheffield, UK. l.tattersall@sheffield.ac.uk.
² Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Ferrara, Italy.
³ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
⁴ Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark.

PMID: 38376653
DOI: 10.1007/s11302-024-09994-x

Abstract

PRESTO was established in 2022 and is a concerted effort by leading European experts in the field of P2XRs and extracellular ATP to promote and advance the transition to the clinic of P2XR-targeting therapies. Following the inaugural meeting in Ferrara which set the foundations of the action and generated interest from many groups and institutes, the second meeting covered the preclinical and clinical aspects of P2XRs as a common route in different diseases, recognising the multidisciplinary and collaborative approach required for a number of medical conditions.

Keywords: ATP; COST Action; P2X; PRESTO; Purinergic signalling.